Daihong H. Liu
Experienced in Splenic Neoplasm

Daihong H. Liu

8 East Street, 
Beijing, CN 
Experienced in Splenic Neoplasm
8 East Street, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Daihong Liu practices in Beijing, China. Liu is rated as an Experienced expert by MediFind in the treatment of Splenic Neoplasm. Their top areas of expertise are Graft Versus Host Disease (GvHD), Leukemia, Acute Myeloid Leukemia (AML), Cytomegalic Inclusion Disease, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 109 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Splenic Neoplasm.

Locations

8 East Street, Beijing, 100071, China
Other Locations
NO. 28 Fuxing Road, Haidian, 100853, China
Fuxing Road 28th, Haidian, 100853, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft-versus- Host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation
Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft-versus- Host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell Transplantation
Enrollment Status: Unknown
Publish Date: April 11, 2023
Intervention Type: Drug
Study Phase: Phase 2
Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
Enrollment Status: Completed
Publish Date: May 24, 2022
Intervention Type: Drug
Study Phase: Phase 4
Low Dose Ruxolitinib in Combination With Methylprednisolone 1mg/kg as Initial Therapy for Acute Graft-Versus-Host Disease
Low Dose Ruxolitinib in Combination With Methylprednisolone 1mg/kg as Initial Therapy for Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Drug: Ruxolitinib+Corticosteroids
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

109 Total Publications

Xenopax is effective for the treatment and prophylaxis of acute graft-versus-host disease.
Xenopax is effective for the treatment and prophylaxis of acute graft-versus-host disease.
Journal: Blood science (Baltimore, Md.)
Published: September 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile